Le Lézard
Classified in: Covid-19 virus

Global Doxorubicin Market Research Report 2022 - ResearchAndMarkets.com

The "Doxorubicin - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Global Doxorubicin Market to Reach $1.3 Billion by 2026

The global market for Doxorubicin estimated at US$992.8 Million in the year 2020, is projected to reach a revised size of US$1.3 Billion by 2026, growing at a CAGR of 5.3% over the analysis period.

Growth in the global market is set to be driven by rising incidence of cancer, development of technologically advanced systems for drug delivery, increasing awareness levels among patients and rising disposable incomes of people. Doxorubicin use is anticipated to increase significantly for ovarian cancer treatment and treatment of AIDS-related Kaposi`s sarcoma following failure of systemic chemotherapy done previously. Increasing number of hepatocellular carcinoma and growing survival rates also constitutes a major growth driver.

Breast Cancer, one of the segments analyzed in the report, is projected to grow at a 5.1% CAGR to reach US$313.8 Million by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Lung Cancer segment is readjusted to a revised 6.9% CAGR for the next 7-year period.

This segment currently accounts for a 16.5% share of the global Doxorubicin market. Breast cancer represents a major category due to the constantly rising prevalence of breast cancer. Myocet, a non-pegylated liposomal doxorubicin, is approved in Canada and the European Union to treat metastatic breast cancer in combination with cyclophosphamide. Increasing incidence of lung cancer and rising awareness about available therapies is fueling demand for doxorubicin.

The U.S. Market is Estimated at $421.1 Million in 2021, While China is Forecast to Reach $106.6 Million by 2026

The Doxorubicin market in the U.S. is estimated at US$421.1 Million in the year 2021. The country currently accounts for a 40.56% share in the global market. China, the world`s second largest economy, is forecast to reach an estimated market size of US$106.6 Million in the year 2026 trailing a CAGR of 7.5% through the analysis period.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.9% and 5.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR while Rest of European market (as defined in the study) will reach US$113.8 Million by the end of the analysis period.

The US represents the largest regional market owing to the presence of a high number of people with different malignant tumors including lung, prostate, bladder, colon, breast and other malignancies. Use of the drug is high in the region, in mono as well as combination chemotherapies.

The well-developed healthcare infrastructure facilities in the country and high adoption of technologically advanced treatment methods for cancer are positioning the US as a major market for cancer therapies. Asia-Pacific represents another key market, due to rising cancer prevalence in the region, increasing awareness about various cancer therapies, and growing collaborations between private and public sectors to offer new cancer therapies in the region.

Ovarian Cancer Segment to Reach $179.7 Million by 2026

Liposomal delivery systems have considerably improved the safety and efficacy of chemotherapeutic agents, in comparison to non-liposomal formulations. The increasing prevalence of ovarian cancer spurs growing use of various forms of liposomal doxorubicin such as Caelyx/Doxil. In the global Ovarian Cancer segment, USA, Canada, Japan, China and Europe will drive the 3.4% CAGR estimated for this segment.

These regional markets accounting for a combined market size of US$122.9 Million in the year 2020 will reach a projected size of US$155.6 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$11.8 Million by the year 2026, while Latin America will expand at a 4.2% CAGR through the analysis period.

Key Topics Covered:




2. FOCUS ON SELECT PLAYERS (Total 59 Featured)





For more information about this report visit https://www.researchandmarkets.com/r/vg3jh9

These press releases may also interest you

at 21:20
The introduction of subscription services for STEM toys is expected to be a key trend of the Science, Technology, Engineering and Mathematics (STEM) Toys Market share growth. Many online retailers provide subscription services for STEM toys in...

at 21:10
Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") announces its audited financial results for the year ended December 31, 2021. All amounts are in Canadian dollars and are prepared in...

at 20:37
In advance of the July 4th Independence Day weekend, the American Association of Kidney Patients (AAKP), the nation's largest independent kidney patient organization, released their annual summer reading list featuring articles by AAKP-affiliated...

at 20:25
K92 Mining Inc. ("K92" or the "Company") is pleased to announce the voting results of its 2022 annual general meeting ("AGM") of shareholders that was held today as a virtual event. All of the resolutions proposed at the meeting were duly passed. A...

at 19:38
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Yext, Inc. between March 4, 2021 and March 8, 2022, both dates inclusive (the "Class Period"), of the important August 16, 2022 lead plaintiff deadline....

at 18:24
As previously announced, Vertical Capital Income Fund paid a monthly distribution of $0.0721 per share to all shareholders of record as of June 17, 2022, pursuant to the Fund's managed distribution plan (the "Plan")....

News published on 23 may 2022 at 06:35 and distributed by: